清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

来那度胺 硼替佐米 泊马度胺 医学 沙利度胺 挽救疗法 内科学 多发性骨髓瘤 伊扎莫布 Carfilzomib公司 自体干细胞移植 肿瘤科 移植 外科 耐火材料(行星科学) 化疗 胃肠病学 物理 天体生物学
作者
Shuji Ozaki,Takeshi Harada,Kengo Udaka,Etsuko Sekimoto,Hironobu Shibata,Toshio Shigekiyo,Hikaru Yagi,Yasunobu Okamoto,Kimiko Sogabe,Masahiro Oura,Shiro Fujii,Shingen Nakamura,Hirokazu Miki,Kumiko Kagawa,Masahiro Abe
出处
期刊:Blood [Elsevier BV]
卷期号:132 (Supplement 1): 5577-5577
标识
DOI:10.1182/blood-2018-99-115818
摘要

Abstract Survival outcome of patients with multiple myeloma (MM) has been markedly improved by the introduction of novel agents such as bortezomib, thalidomide, and lenalidomide over the past decade. Recent clinical studies have shown further improvement by second-generation agents, namely carfilzomib, ixazomib, pomalidomide, elotuzumab, and daratumumab. However, the prognosis of patients who became refractory to both bortezomib and lenalidomide was extremely poor, and the efficacy of the second-generation agents in such patient remains unclear in routine clinical practice. In this study, we analyzed the outcome of MM patients in terms of overall survival (OS) and survival time after salvage therapy. A total of 174 patients (89 male and 85 female) treated between 2003 and 2017 were enrolled. The median age was 69 years old (range 35-89). The type of M protein was IgG in 93, IgA in 35, IgD in 10, Bence Jones type in 30, and non-secretory type in 5 patients, respectively. The international staging system (ISS) stages I, II, and III were 32, 66, and 63 patients, respectively. There were 100 patients with normal serum LDH and 39 with high LDH. As for initial therapy, 62 patients were treated with conventional chemotherapy, 83 with bortezomib-based regimens, 7 with lenalidomide-based regimens, and 22 with bortezomib + lenalidomide + dexamethasone. Forty-seven patients received autologous stem cell transplantation in the upfront setting. During the observation period 120 patients relapsed and 6 were refractory to initial therapy, and 38 patients were treated with conventional chemotherapy and 58 with the first-generation novel agents such as bortezomib, lenalidomide, or thalidomide as salvage therapy. The remaining 30 patients were further treated with the second-generation novel agents such as carfilzomib in 21, ixazomib in 5, pomalidomide in 6, elotuzumab in 4, or daratumumab in 8 patients after refractory to bortezomib and lenalidomide. The median progression-free survival was 17.7 months and the median OS was 51.0 months from initial therapy. Regarding the outcome according to salvage therapy, the median OS was 22.0 months for conventional chemotherapy group, 46.4 months for first-generation agent group, and 98.7 months for second-generation agent group (p<0.0001). The survival of the second-generation group was longer compared with the first-generation group in both transplanted (median OS, 80.5 vs 118.3 months) and non-transplanted patients (39.2 vs 56.6 months). In patients who received the first-generation agents as initial therapy, the median OS was 45.1 months for the first-generation group and 71.5 months for the second-generation group. In the survival time after salvage therapy, the median survival was 18.6 months, and there was no significant difference by initial therapy (16.8 months for conventional chemotherapy group and 20.1 months for novel agent group). According to salvage therapy, the median survival after salvage therapy was 7.5 months for conventional chemotherapy group, 20.4 months for first-generation agent group, and 29.5 months for second-generation agent group (p<0.001, Figure). The survival benefit after salvage therapy with the second-generation agents was also observed in both transplanted (median survival after salvage, 29.5 vs 69.8 months) and non-transplanted patients (18.6 vs 23.6 months). In patients who received the first-generation agents as initial therapy, the median survival after salvage was 25.0 months for the first-generation group and 29.5 months for the second-generation group, and again survival time was longer in the second-generation group. Regarding the risk factors, the median survivals after second-generation novel agent therapy were not reached, 69.8, and 14.8 months in the ISS I, II, and III stages, respectively, and were 69.8 and 14.8 months in normal and high LDH groups, respectively. Thus, our results have demonstrated that the second-generation novel agents significantly prolonged survival in relapsed and refractory patients regardless of the use of the first-generation agents. However, the survival benefit was mostly observed in standard risk and transplanted patients but not in high-risk patients. Therefore, further studies are needed to establish more effective strategies using the next generation agents in routine clinical practice. Figure. Figure. Disclosures No relevant conflicts of interest to declare.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
搜集达人的应助被科研通管家采纳,获得10
1秒前
1秒前
zilicai的应助被科研通管家采纳,获得10
1秒前
星辰大海的应助被科研通管家采纳,获得10
1秒前
2秒前
ding的应助被科研通管家采纳,获得10
2秒前
烂漫的诗蕊完成签到,获得积分10
2秒前
2秒前
physicalpicture完成签到,获得积分10
6秒前
广州小肥羊完成签到 ,获得积分10
33秒前
38秒前
高高的玉兰完成签到,获得积分10
41秒前
体贴的惜文完成签到,获得积分10
42秒前
49秒前
KalEl发布了新的文献求助10
49秒前
55秒前
irisxiong完成签到,获得积分10
56秒前
笔墨纸砚完成签到 ,获得积分10
1分钟前
务实的海豚完成签到,获得积分10
1分钟前
共享精神的应助被兰兰不懒采纳,获得10
1分钟前
vbnn完成签到 ,获得积分10
1分钟前
天很蓝完成签到,获得积分10
1分钟前
饱满飞绿完成签到,获得积分10
1分钟前
子凡完成签到 ,获得积分10
1分钟前
自由的冷玉完成签到,获得积分10
1分钟前
风息完成签到,获得积分10
1分钟前
1分钟前
会飞的鹦鹉完成签到,获得积分10
1分钟前
兰兰不懒发布了新的文献求助10
2分钟前
2分钟前
2分钟前
科研通AI65的应助被科研通管家采纳,获得10
2分钟前
2分钟前
Maestro_S的应助被科研通管家采纳,获得10
2分钟前
SAY完成签到 ,获得积分10
2分钟前
fantasy的应助被shine采纳,获得10
2分钟前
激动的似狮完成签到,获得积分10
2分钟前
2分钟前
KalEl发布了新的文献求助10
2分钟前
chemlink完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190226
求助须知:如何正确求助?哪些是违规求助? 9577355
关于积分的说明 21852358
捐赠科研通 7788746
什么是DOI,文献DOI怎么找? 3436310
关于科研通互助平台的介绍 2560106
邀请新用户注册赠送积分活动 2482911